Peptide Database

HCG mimics luteinizing hormone and is the most evidence-backed option for preserving fertility and testicular volume during TRT. The Coviello 2005 dose-response trial confirmed that low doses maintain intratesticular testosterone, though brand-name pricing after the 2020 compounding ban remains a real barrier.

Semaglutide holds four FDA approvals for obesity, type 2 diabetes, and cardiovascular risk reduction. STEP 1 confirmed 14.9% mean weight loss at 68 weeks. The 7.2 mg high-dose version (March 2026) pushes that to 20.7%. GI side effects are real but manageable with slow titration.

Leuprolide (Lupron) is an FDA-approved GnRH agonist prescribed for prostate cancer, endometriosis, uterine fibroids, and precocious puberty. Depot formulations cover monthly to six-month dosing. The initial hormone flare requires careful management, and bone density monitoring is standard during therapy. Over 4,160 PubMed publications support its clinical profile.

Tirzepatide targets both GIP and GLP-1 receptors, producing 20-22% body weight loss in important trials. FDA-approved as Zepbound (obesity) and Mounjaro (T2D). GI side effects during titration are the main limiting factor; a black box warning for thyroid tumors applies.

TRT (Testosterone Replacement Therapy) restores testosterone in hypogonadal men using FDA approved injectable cypionate. The TRAVERSE trial (n=5,246) confirmed cardiovascular safety. Split dosing twice weekly is now standard at most clinics. Total testosterone targets typically run 500 to 800 ng/dL.

CJC-1295 plus Ipamorelin is the most popular pre-mixed GH secretagogue stack, valued for clean growth hormone release without cortisol or appetite spikes. Sleep improvements appear within two weeks. Body composition shifts follow by month two. No RCT exists for the combo, but individual-component data and thousands of community reports align closely.

BPC-157 is the most popular healing peptide in the world, backed by 180+ PubMed papers and consistent user reports from tens of thousands of people. Community evidence for tendon and gut repair is hard to dismiss, though formal human trials remain limited to about 30 subjects total.

Retatrutide is a triple-agonist peptide (GLP-1, GIP, glucagon) that produced 28.7% weight loss in Phase 3 at 68 weeks. Not yet FDA approved. Strongest clinical weight loss data of any drug tested to date, with liver fat reduction exceeding 80% in MASLD subgroups.

TB-500 is the most popular systemic healing peptide in the research community, with 500+ forum threads and a 4.1/5 sentiment score. Backed by strong preclinical wound-healing data but zero completed human trials for the fragment itself. Inject anywhere; it reaches the injury regardless of site.

MK-677 (Ibutamoren) is an oral growth hormone secretagogue backed by a 2-year RCT in healthy elderly adults. It raises IGF-1 40 to 60 percent without suppressing your natural GH axis. Appetite stimulation and insulin resistance are the main limitations. Research compound, not FDA approved.

Ipamorelin is the most selective growth hormone releasing peptide available, producing a clean GH pulse without spiking cortisol, prolactin, or appetite. Community evidence across hundreds of threads is strong. No human efficacy trial has passed yet. Most users cycle 8 to 12 weeks.

The Wolverine Stack (BPC-157 + TB-500) combines two healing peptides in one pre-mixed vial. One published human combination report showed 14/16 patients with significant pain relief. Tens of thousands of community reports back up the science. No dedicated clinical trial exists yet, but this remains the most popular healing stack available.

NAD+ injectable protocols produce rapid cellular energy restoration and sirtuin activation. A 2019 IV infusion study confirmed 398% plasma elevation above baseline. Subcutaneous maintenance dosing at 100 to 250 mg twice weekly is the community standard for longevity use, though RCT evidence for wellness claims is still catching up.

CJC-1295 (No DAC) triggers natural GH pulses with a 30-minute half-life. Paired with Ipamorelin in most protocols, it's the community's preferred GHRH analog for sleep, recovery, and body composition. No clinical trials of any kind exist for this specific form.

PT-141 (bremelanotide) is the only FDA-approved peptide targeting sexual desire through MC4R activation. The RECONNECT Phase 3 trials confirmed efficacy in 1,247 women with HSDD. Nausea hits 40% of users but typically improves after the first few doses with repeat use.

Argireline is a topical hexapeptide that inhibits SNARE complex assembly to soften expression wrinkles. Clinical results range from 48.9% efficacy to no significant effect across controlled trials. At $10 per bottle, it's worth testing on your own skin before drawing conclusions.

HGH (Somatropin) is FDA-approved recombinant growth hormone with clinical trial data spanning 15,809 patients. Rudman's foundational study showed 8.8% lean mass gain and 14.4% fat loss in six months. Pharma-grade pricing remains steep, but anti-aging protocols at 1 to 2 IU daily are the community standard for sleep, skin, and body composition.

Gonadorelin is the synthetic form of GnRH, FDA-approved since 1978. Used alongside TRT to preserve testicular function and fertility. Dosing frequency matters more than dose size; its 2 to 40 minute half-life makes protocol design the key deciding factor.

Octreotide is an FDA-approved somatostatin analog with three labeled indications and 35+ years of clinical data. The PROMID trial showed it doubled time to tumor progression in midgut NETs. Near-complete subcutaneous bioavailability, but gallstones affect up to 65% of long-term users. Supplied as a pre-filled solution.

Alpha-MSH is the parent peptide behind the melanocortin anti-inflammatory pathway, backed by 6,500+ published studies. Two FDA-approved drugs target the same receptor family. Native alpha-MSH's 20-minute half-life limits practical use; most users choose KPV, its active C-terminal fragment, for anti-inflammatory applications instead.

Liraglutide is an FDA-approved GLP-1 receptor agonist with 15+ years of market data and proven cardiovascular protection from the LEADER trial (n=9,340). Less potent than semaglutide for weight loss, but side effects clear in a day thanks to its 13-hour half-life.

Glucagon reverses severe hypoglycemia in 10 to 15 minutes by mobilizing liver glycogen stores. Three FDA-approved formulations cover injection and nasal delivery. It won't work if glycogen is depleted from fasting, alcohol, or adrenal insufficiency. Caregivers should keep one on hand.

Glutathione is a tripeptide antioxidant produced in every cell, but oral bioavailability sits around 10%. Injectable routes deliver 100% to circulation. One RCT showed skin brightening in 37.5% of subjects after 12 IV sessions. Community protocols center on 200 to 400 mg subcutaneous, two to three times weekly. No FDA-approved injectable product exists.

AICAR activates AMPK, the same metabolic sensor that fires during exercise. Banned by WADA since 2009 after mouse studies showed 44% endurance gains. Community doses are roughly 500x below animal study levels, so real-world effects remain subtle and debated among a small user base.